Anti-TNF therapy resulted in a greater reduction in aphthous ulceration in both Crohn's disease and UC than anti-integrin therapy, but it was acknowledged that this may reflect a more severe disease phenotype in the anti-integrin cohort, as these are generally second line agents. Here, TNF is linked to Crohn disease.